Aim and Scope

Journal of Clinical Trials in Oncology​ aims to publish the original articles on all aspects of the conventional plant breeding methods and agronomic techniques that makes advance our understanding of Clinical Trials of Oncology principles and strategies. 

JCTO presents high visibility for author’s work by indexing in various indexing sites and also provides free access to a broad readership with enhanced innovative web technologies, including interactive browsing and efficient data- and text-mining. 

JCTO publishes a broad range of Cancer and Oncology research articles including, but not limited to:

Radiation Oncology
Cancer immunotherapy
Cancer Biomarkers
Mutagenesis
Gene therapy and Immunotherapy
Pediatric Oncology
Oncogenomics, proteomics and metabolomics
Tumor and stem cell biology
Side Effects of Cancer Therapies
Carcinogenic Viruses
Anti Cancer Drugs
Apoptosis
Cancer Cell Biology
Cancer Biology
Brest cancer
Ovarian Cancer
General Oncology
Cancer Risks
Clinical Trials and Epidemiology
Tumor suppressor genes
Leukemia 


Publication of article types:    

Research articles: should report new scientific insights, original technologies or novel methods and must not have been previously published elsewhere, except in a preliminary form.

Review articles: Review articles should provide information about timely syntheses of topical themes that propose new ideas or a provocative new direction for a discipline within the specified topic.

 Short communication:  Should be presented with scientific significant content without exceeding more than 3000 words.

 Case reports: Any clinical case or procedure that illustrates an important best practice clinical guideline and cases which enhance understanding of disease process, its diagnosis, management and clinicopathological correlation.

Editorials: Should be describing the current trends in particular field within aim and scope of the Journal. 

As Journal of Clinical Trials in Oncology​ follows the Creative Commons Attribution License and scholars open access publishing policies, readers can freely access the published articles through online and JCTO will be kept up to date with latest advances in the field of cancer. All published articles will be assigned with unique Digital Objective Identifier provided by Cross Ref.


top